Companies: 10,795·Total market cap: $144.5T
CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.

CTMXNASDAQHealthcare● Active
$2.94
$-0.06(-1.87%)
Market Cap$473432305
P/E Ratio
52W High$8.21
52W Low$1.72
SEC Filings

CytomX Therapeutics, Inc. (CTMX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001501989 · CTMX · NASDAQ · as of Jun 8, 2026

Filing snapshot

774
Total Filings
8-K
Latest Form
2026-06-03
Most Recent
2015
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001501989 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-16
Fiscal Year End
Mar 16, 2026
Accession No.
0001193125-26-107146
Primary Document
ctmx-20251231.htm
Source: data.sec.gov · CIK 0001501989 · Accession 0001193125-26-107146

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-06-03Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-03
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
8-K
2026-05-07
View
10-QQuarterly Report
10-Q
2026-05-07
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-30
View
DEF 14AProxy Statement
DEF 14A
2026-04-30
View
PRE 14APRE 14A
PRE 14A
2026-04-20
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-16
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-19
View
424B5424B5
424B5
2026-03-18
View
Showing 1–15 of 423 filingsForm 4 / 144 hidden· 774 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001501989  |  Exchange: NASDAQ · Healthcare

CytomX Therapeutics, Inc. (NASDAQ: CTMX) has submitted 774 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001501989, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is CytomX Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent CytomX Therapeutics, Inc. 10-K was filed on 2026-03-16 for fiscal year ending 2026. Historical CTMX 10-K annual reports are available from 2010 through 2026.

Investors researching CytomX Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

CTMX SEC Filings · 8 questions

CytomX Therapeutics, Inc. (CTMX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 774 filings and access original documents at no cost. CytomX Therapeutics, Inc.'s CIK is 0001501989.

CTMX SEC filingsCytomX Therapeutics, Inc. SEC documentsfind CTMX 10-K